Covid-19 Research

Open Access
Review Article
OCLC

Bleeding and Thrombotic Complications in Patients with Premalignant Hematologic Conditions: Diagnostic and Therapeutic Challenges Google Scholar

Read • Cite • Share — permanent Open Access hosting with DOI tracking

Nowroozi M*

Volume7-Issue2
Dates: Received: 2025-11-21 | Accepted: 2026-02-15 | Published: 2026-02-19
Pages: 1-17

Abstract

Premalignant hematology patients categorized as monoclonal B-cell lymphocytosis, clonal cytopenia of indeterminate importance, monoclonal gammopathy of unknown relevance, and clonal hematopoiesis. These disorders are categorized as premalignant due to their clonal proliferation of myeloid, lymphoid, or plasma cells, without meeting the criteria for active hematologic malignancy or precancers; clinical manifestations, diagnosis, and management of these conditions are critical components of this topic. This review encompasses the most recently published articles and studies relevant to the article titles and the methodologies of isolation conducted without electronic instruments. The purpose of this review paper is to draw attention to the challenges related to bleeding, thrombosis, and diagnosis. The articles' outcomes rely on changes in treatment and diagnosis, as there has been no acceptable medication for a long time. One of the most common problems is side effects during therapy, like infections and neutropenia, which have resulted in one treatment-related death. Considering the connection between thrombosis and therapy in premalignant patients, when there is insufficient information to accept the excess bleeding and thrombosis in premalignant hematological patients.

FullText HTML FullText PDF DOI: 10.37871/jbres2269


Certificate of Publication




Copyright

© 2026 Nowroozi M. Distributed under Creative Commons CC-BY 4.0

How to cite this article

Nowroozi M.Bleeding and Thrombotic Complications in Patients with Premalignant Hematologic Conditions: Diagnostic and Therapeutic Challenges. J Biomed Res Environ Sci. 2026 Feb 19; 7(2): 17. Doi: 10.37871/jbres2269


Subject area(s)

References


  1. Liu Y, Desai P, Nadeem O, Woyach JA, Alsouqi A. Precursor Hematologic Conditions: Diagnosis, Risk Stratification, Clinical Implications, and Management. Am Soc Clin Oncol Educ Book. 2025 Jun;45(3):e473650. doi: 10.1200/EDBK-25-473650. Epub 2025 Jun 11. PMID: 40499077.
  2. Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024 Jan-Feb;74(1):12-49. doi: 10.3322/caac.21820. Epub 2024 Jan 17. Erratum in: CA Cancer J Clin. 2024 Mar-Apr;74(2):203. doi: 10.3322/caac.21830. PMID: 38230766.
  3. Nardi V, Kuo FC, Hasserjian RP. Premalignant Clonal Hematopoietic Proliferations. Am J Clin Pathol. 2019 Aug 1;152(3):347-358. doi: 10.1093/ajcp/aqz079. PMID: 31305863.
  4. Genovese G, Kähler AK, Handsaker RE, Lindberg J, Rose SA, Bakhoum SF, Chambert K, Mick E, Neale BM, Fromer M, Purcell SM, Svantesson O, Landén M, Höglund M, Lehmann S, Gabriel SB, Moran JL, Lander ES, Sullivan PF, Sklar P, Grönberg H, Hultman CM, McCarroll SA. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014 Dec 25;371(26):2477-87. doi: 10.1056/NEJMoa1409405. Epub 2014 Nov 26. PMID: 25426838; PMCID: PMC4290021.
  5. Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, Lindsley RC, Mermel CH, Burtt N, Chavez A, Higgins JM, Moltchanov V, Kuo FC, Kluk MJ, Henderson B, Kinnunen L, Koistinen HA, Ladenvall C, Getz G, Correa A, Banahan BF, Gabriel S, Kathiresan S, Stringham HM, McCarthy MI, Boehnke M, Tuomilehto J, Haiman C, Groop L, Atzmon G, Wilson JG, Neuberg D, Altshuler D, Ebert BL. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014 Dec 25;371(26):2488-98. doi: 10.1056/NEJMoa1408617. Epub 2014 Nov 26. PMID: 25426837; PMCID: PMC4306669.
  6. Busque L, Patel JP, Figueroa ME, Vasanthakumar A, Provost S, Hamilou Z, Mollica L, Li J, Viale A, Heguy A, Hassimi M, Socci N, Bhatt PK, Gonen M, Mason CE, Melnick A, Godley LA, Brennan CW, Abdel-Wahab O, Levine RL. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet. 2012 Nov;44(11):1179-81. doi: 10.1038/ng.2413. Epub 2012 Sep 23. PMID: 23001125; PMCID: PMC3483435.
  7. Slape CI. Pre-Leukemic States: United by Difference. Cancers (Basel). 2021 Mar 18;13(6):1382. doi: 10.3390/cancers13061382. PMID: 33803727; PMCID: PMC8003200.
  8. Wang TF, Leader A, Sanfilippo KM. Thrombosis and bleeding in hematological malignancy. Best Pract Res Clin Haematol. 2022 Mar;35(1):101353. doi: 10.1016/j.beha.2022.101353. Epub 2022 Jun 16. PMID: 36030068.
  9. Navi BB, Reiner AS, Kamel H, Iadecola C, Okin PM, Elkind MSV, Panageas KS, DeAngelis LM. Reply: Arterial Thromboembolism in Non-Hodgkin Lymphoma, as the Presentation of Occult Cancer, and With Cancer Therapies. J Am Coll Cardiol. 2018 Jan 16;71(2):260-262. doi: 10.1016/j.jacc.2017.10.088. PMID: 29325653.
  10. Sorigue M, Sarrate E, Franch M, Sancho JM. Arterial Thromboembolism in Non-Hodgkin Lymphoma. J Am Coll Cardiol. 2018 Jan 16;71(2):258-259. doi: 10.1016/j.jacc.2017.09.1155. PMID: 29325650.
  11. Ghia P, Prato G, Scielzo C, Stella S, Geuna M, Guida G, Caligaris-Cappio F. Monoclonal CD5+ and CD5- B-lymphocyte expansions are frequent in the peripheral blood of the elderly. Blood. 2004 Mar 15;103(6):2337-42. doi: 10.1182/blood-2003-09-3277. Epub 2003 Nov 20. PMID: 14630808.
  12. Marti GE, Rawstron AC, Ghia P, Hillmen P, Houlston RS, Kay N, Schleinitz TA, Caporaso N; International Familial CLL Consortium. Diagnostic criteria for monoclonal B-cell lymphocytosis. Br J Haematol. 2005 Aug;130(3):325-32. doi: 10.1111/j.1365-2141.2005.05550.x. PMID: 16042682.
  13. Saiki R, Momozawa Y, Nannya Y, Nakagawa MM, Ochi Y, Yoshizato T, Terao C, Kuroda Y, Shiraishi Y, Chiba K, Tanaka H, Niida A, Imoto S, Matsuda K, Morisaki T, Murakami Y, Kamatani Y, Matsuda S, Kubo M, Miyano S, Makishima H, Ogawa S. Combined landscape of single-nucleotide variants and copy number alterations in clonal hematopoiesis. Nat Med. 2021 Jul;27(7):1239-1249. doi: 10.1038/s41591-021-01411-9. Epub 2021 Jul 8. PMID: 34239136.
  14. Burnworth B, Wang Z, Singleton TP, Bennington A, Fritschle W, Bennington R, Brodersen LE, Wells DA, Loken MR, Zehentner BK. Clone-specific MYD88 L265P and CXCR4 mutation status can provide clinical utility in suspected Waldenström macroglobulinemia/lymphoplasmacytic lymphoma. Leuk Res. 2016 Dec;51:41-48. doi: 10.1016/j.leukres.2016.10.008. Epub 2016 Oct 18. PMID: 27890075.
  15. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating M, Montserrat E, Chiorazzi N, Stilgenbauer S, Rai KR, Byrd JC, Eichhorst B, O'Brien S, Robak T, Seymour JF, Kipps TJ. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018 Jun 21;131(25):2745-2760. doi: 10.1182/blood-2017-09-806398. Epub 2018 Mar 14. PMID: 29540348.
  16. Marti GE, Carter P, Abbasi F, Washington GC, Jain N, Zenger VE, Ishibe N, Goldin L, Fontaine L, Weissman N, Sgambati M, Fauget G, Bertin P, Vogt RF Jr, Slade B, Noguchi PD, Stetler-Stevenson MA, Caporaso N. B-cell monoclonal lymphocytosis and B-cell abnormalities in the setting of familial B-cell chronic lymphocytic leukemia. Cytometry B Clin Cytom. 2003 Mar;52(1):1-12. doi: 10.1002/cyto.b.10013. PMID: 12599176.
  17. Kyle RA, Larson DR, Therneau TM, Dispenzieri A, Kumar S, Cerhan JR, Rajkumar SV. Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance. N Engl J Med. 2018 Jan 18;378(3):241-249. doi: 10.1056/NEJMoa1709974. PMID: 29342381; PMCID: PMC5852672.
  18. Ekladious A, Bhandari R, Javaid MM. Association of monoclonal gammopathy of undetermined significance and C3 glomerulopathy. Intern Med J. 2023 Sep;53(9):1712-1715. doi: 10.1111/imj.16222. Epub 2023 Sep 4. PMID: 37665716.
  19. Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E, Richardson P, Landgren O, Paiva B, Dispenzieri A, Weiss B, LeLeu X, Zweegman S, Lonial S, Rosinol L, Zamagni E, Jagannath S, Sezer O, Kristinsson SY, Caers J, Usmani SZ, Lahuerta JJ, Johnsen HE, Beksac M, Cavo M, Goldschmidt H, Terpos E, Kyle RA, Anderson KC, Durie BG, Miguel JF. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014 Nov;15(12):e538-48. doi: 10.1016/S1470-2045(14)70442-5. Epub 2014 Oct 26. PMID: 25439696.
  20. Therneau TM, Kyle RA, Melton LJ 3rd, Larson DR, Benson JT, Colby CL, Dispenzieri A, Kumar S, Katzmann JA, Cerhan JR, Rajkumar SV. Incidence of monoclonal gammopathy of undetermined significance and estimation of duration before first clinical recognition. Mayo Clin Proc. 2012 Nov;87(11):1071-9. doi: 10.1016/j.mayocp.2012.06.014. Epub 2012 Aug 7. PMID: 22883742; PMCID: PMC3541934.
  21. Fermand JP, Bridoux F, Dispenzieri A, Jaccard A, Kyle RA, Leung N, Merlini G. Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications. Blood. 2018 Oct 4;132(14):1478-1485. doi: 10.1182/blood-2018-04-839480. Epub 2018 Jul 16. PMID: 30012636.
  22. Malcovati L, Gallì A, Travaglino E, Ambaglio I, Rizzo E, Molteni E, Elena C, Ferretti VV, Catricalà S, Bono E, Todisco G, Bianchessi A, Rumi E, Zibellini S, Pietra D, Boveri E, Camaschella C, Toniolo D, Papaemmanuil E, Ogawa S, Cazzola M. Clinical significance of somatic mutation in unexplained blood cytopenia. Blood. 2017 Jun 22;129(25):3371-3378. doi: 10.1182/blood-2017-01-763425. Epub 2017 Apr 19. PMID: 28424163; PMCID: PMC5542849.
  23. Rajkumar SV, Landgren O, Mateos MV. Smoldering multiple myeloma. Blood. 2015 May 14;125(20):3069-75. doi: 10.1182/blood-2014-09-568899. Epub 2015 Apr 2. PMID: 25838344; PMCID: PMC4432003.
  24. Kulkarni A, Bazou D, Santos-Martinez MJ. Bleeding and Thrombosis in Multiple Myeloma: Platelets as Key Players during Cell Interactions and Potential Use as Drug Delivery Systems. Int J Mol Sci. 2023 Nov 1;24(21):15855. doi: 10.3390/ijms242115855. PMID: 37958838; PMCID: PMC10647631.
  25. Ravindran A, Bartley AC, Holton SJ, Gonsalves WI, Kapoor P, Siddiqui MA, Hashmi SK, Marshall AL, Ashrani AA, Dispenzieri A, Kyle RA, Rajkumar SV, Go RS. Prevalence, incidence and survival of smoldering multiple myeloma in the United States. Blood Cancer J. 2016 Oct 21;6(10):e486. doi: 10.1038/bcj.2016.100. PMID: 27768092; PMCID: PMC5098258.
  26. Valent P, Orazi A, Steensma DP, Ebert BL, Haase D, Malcovati L, van de Loosdrecht AA, Haferlach T, Westers TM, Wells DA, Giagounidis A, Loken M, Orfao A, Lübbert M, Ganser A, Hofmann WK, Ogata K, Schanz J, Béné MC, Hoermann G, Sperr WR, Sotlar K, Bettelheim P, Stauder R, Pfeilstöcker M, Horny HP, Germing U, Greenberg P, Bennett JM. Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions. Oncotarget. 2017 Jul 5;8(43):73483-73500. doi: 10.18632/oncotarget.19008. PMID: 29088721; PMCID: PMC5650276.
  27. Gibson SE, Swerdlow SH, Ferry JA, Surti U, Dal Cin P, Harris NL, Hasserjian RP. Reassessment of small lymphocytic lymphoma in the era of monoclonal B-cell lymphocytosis. Haematologica. 2011 Aug;96(8):1144-52. doi: 10.3324/haematol.2011.042333. Epub 2011 May 5. PMID: 21546505; PMCID: PMC3148908.
  28. Valent P, Akin C, Arock M, Bock C, George TI, Galli SJ, Gotlib J, Haferlach T, Hoermann G, Hermine O, Jäger U, Kenner L, Kreipe H, Majeti R, Metcalfe DD, Orfao A, Reiter A, Sperr WR, Staber PB, Sotlar K, Schiffer C, Superti-Furga G, Horny HP. Proposed Terminology and Classification of Pre-Malignant Neoplastic Conditions: A Consensus Proposal. EBioMedicine. 2017 Dec;26:17-24. doi: 10.1016/j.ebiom.2017.11.024. Epub 2017 Nov 26. PMID: 29203377; PMCID: PMC5832623.
  29. Valent P, Horny HP. Minimal diagnostic criteria for myelodysplastic syndromes and separation from ICUS and IDUS: update and open questions. Eur J Clin Invest. 2009 Jul;39(7):548-53. doi: 10.1111/j.1365-2362.2009.02151.x. Epub 2009 May 6. PMID: 19453651.
  30. Cook EK, Izukawa T, Young S, Rosen G, Jamali M, Zhang L, Johnson D, Bain E, Hilland J, Ferrone CK, Buckstein J, Francis J, Momtaz B, McNaughton AJM, Liu X, Snetsinger B, Buckstein R, Rauh MJ. Comorbid and inflammatory characteristics of genetic subtypes of clonal hematopoiesis. Blood Adv. 2019 Aug 27;3(16):2482-2486. doi: 10.1182/bloodadvances.2018024729. PMID: 31434682; PMCID: PMC6712533.
  31. Xie Z, Smith A, Komrokji RS, Al Ali N, Patel AA, Saygin C. The Characteristics and prognosis of patients with clonal cytopenias of undetermined significance, including cancer and therapy-related clonal cytopenias. Blood. 2022;140:2887-90.
  32. Steensma DP, Bejar R, Jaiswal S, Lindsley RC, Sekeres MA, Hasserjian RP, Ebert BL. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood. 2015 Jul 2;126(1):9-16. doi: 10.1182/blood-2015-03-631747. Epub 2015 Apr 30. PMID: 25931582; PMCID: PMC4624443.
  33. Acuna-Hidalgo R, Sengul H, Steehouwer M, van de Vorst M, Vermeulen SH, Kiemeney LALM, Veltman JA, Gilissen C, Hoischen A. Ultra-sensitive Sequencing Identifies High Prevalence of Clonal Hematopoiesis-Associated Mutations throughout Adult Life. Am J Hum Genet. 2017 Jul 6;101(1):50-64. doi: 10.1016/j.ajhg.2017.05.013. Epub 2017 Jun 29. PMID: 28669404; PMCID: PMC5501773.
  34. Miller PG, Steensma DP. Implications of Clonal Hematopoiesis for Precision Oncology. JCO Precis Oncol. 2020 Nov;4:639-646. doi: 10.1200/PO.20.00144. PMID: 35050749.
  35. Watson CJ, Papula AL, Poon GYP, Wong WH, Young AL, Druley TE, Fisher DS, Blundell JR. The evolutionary dynamics and fitness landscape of clonal hematopoiesis. Science. 2020 Mar 27;367(6485):1449-1454. doi: 10.1126/science.aay9333. PMID: 32217721.
  36. Goldman EA, Spellman PT, Agarwal A. Defining clonal hematopoiesis of indeterminate potential: evolutionary dynamics and detection under aging and inflammation. Cold Spring Harb Mol Case Stud. 2023 May 9;9(2):a006251. doi: 10.1101/mcs.a006251. PMID: 36889927; PMCID: PMC10240836.
  37. Steensma DP, Ebert BL. Clonal hematopoiesis as a model for premalignant changes during aging. Exp Hematol. 2020 Mar;83:48-56. doi: 10.1016/j.exphem.2019.12.001. Epub 2019 Dec 12. PMID: 31838005; PMCID: PMC7103509.
  38. Jaiswal S, Natarajan P, Silver AJ, Gibson CJ, Bick AG, Shvartz E, McConkey M, Gupta N, Gabriel S, Ardissino D, Baber U, Mehran R, Fuster V, Danesh J, Frossard P, Saleheen D, Melander O, Sukhova GK, Neuberg D, Libby P, Kathiresan S, Ebert BL. Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease. N Engl J Med. 2017 Jul 13;377(2):111-121. doi: 10.1056/NEJMoa1701719. Epub 2017 Jun 21. PMID: 28636844; PMCID: PMC6717509.
  39. Kristinsson SY, Pfeiffer RM, Björkholm M, Goldin LR, Schulman S, Blimark C, Mellqvist UH, Wahlin A, Turesson I, Landgren O. Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study. Blood. 2010 Jun 17;115(24):4991-8. doi: 10.1182/blood-2009-11-252072. Epub 2010 Mar 18. Erratum in: Blood. 2011 Apr 7;117(14):3938. PMID: 20299513; PMCID: PMC2890150.
  40. Sigurbergsdóttir AÝ, Rögnvaldsson S, Thorsteinsdóttir S, Sverrisdóttir I, Sigurðardóttir GÁ, Viðarsson B, Önundarson PT, Agnarsson BA, Sigurðardóttir M, Þorsteinsdóttir I, Ólafsson Í, Þórðardóttir ÁR, Gíslason GK, Ólafsson A, Hultcrantz M, Durie BGM, Harding S, Landgren O, Löve TJ, Kristinsson SY. Disease associations with monoclonal gammopathy of undetermined significance can only be evaluated using screened cohorts: results from the population-based iStopMM study. Haematologica. 2023 Dec 1;108(12):3392-3398. doi: 10.3324/haematol.2023.283191. PMID: 37439374; PMCID: PMC10690899.
  41. Dispenzieri A, Katzmann JA, Kyle RA, Larson DR, Melton LJ 3rd, Colby CL, Therneau TM, Clark R, Kumar SK, Bradwell A, Fonseca R, Jelinek DF, Rajkumar SV. Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. Lancet. 2010 May 15;375(9727):1721-8. doi: 10.1016/S0140-6736(10)60482-5. Erratum in: Lancet. 2010 Jul 31;376(9738):332. doi: 10.1016/S0140-6736(10)61186-5. PMID: 20472173; PMCID: PMC2904571.
  42. Rassy EE, Tabchi S, Haddad FG, Chebib R, Assi T, Kourie HR, Nasr F. Acquired factor inhibitor in a patient with monoclonal gammopathy of undetermined significance responding to rituximab. Blood Coagul Fibrinolysis. 2016 Oct;27(7):822-824. doi: 10.1097/MBC.0000000000000472. PMID: 26626040.
  43. McQuilten ZK, Thao LTP, Bick AG, Byars S, Chan AT, Ford L, Leichter A, McNeil JJ, Murray AM, Murphy AJ, Orchard SG, Phung J, Ramshaw HS, Singh J, Tonkin AM, Umar A, Wolfe R, Wood EM, Woods RL, Lacaze P, Curtis DJ. Clonal Hematopoiesis and Cardiovascular Disease and Bleeding Risk and the Effectiveness of Aspirin. JAMA Cardiol. 2025 Dec 1;10(12):1257-1266. doi: 10.1001/jamacardio.2025.3756. PMID: 41091476; PMCID: PMC12529328.
  44. Veninga A, De Simone I, Heemskerk JWM, Cate HT, van der Meijden PEJ. Clonal hematopoietic mutations linked to platelet traits and the risk of thrombosis or bleeding. Haematologica. 2020 Aug;105(8):2020-2031. doi: 10.3324/haematol.2019.235994. Epub 2020 Jun 18. PMID: 32554558; PMCID: PMC7395290.
  45. Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020 May;95(5):548-567. doi: 10.1002/ajh.25791. Erratum in: Am J Hematol. 2020 Nov;95(11):1444. doi: 10.1002/ajh.25876. PMID: 32212178.
  46. Landgren O, Kyle RA, Pfeiffer RM, Katzmann JA, Caporaso NE, Hayes RB, Dispenzieri A, Kumar S, Clark RJ, Baris D, Hoover R, Rajkumar SV. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood. 2009 May 28;113(22):5412-7. doi: 10.1182/blood-2008-12-194241. Epub 2009 Jan 29. PMID: 19179464; PMCID: PMC2689042.
  47. Weiss BM, Abadie J, Verma P, Howard RS, Kuehl WM. A monoclonal gammopathy precedes multiple myeloma in most patients. Blood. 2009 May 28;113(22):5418-22. doi: 10.1182/blood-2008-12-195008. Epub 2009 Feb 20. PMID: 19234139; PMCID: PMC2689043.
  48. Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, Dispenzieri A, Katzmann JA, Melton LJ 3rd. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006 Mar 30;354(13):1362-9. doi: 10.1056/NEJMoa054494. PMID: 16571879.
  49. Murray D, Kumar SK, Kyle RA, Dispenzieri A, Dasari S, Larson DR, Vachon C, Cerhan JR, Rajkumar SV. Detection and prevalence of monoclonal gammopathy of undetermined significance: a study utilizing mass spectrometry-based monoclonal immunoglobulin rapid accurate mass measurement. Blood Cancer J. 2019 Dec 13;9(12):102. doi: 10.1038/s41408-019-0263-z. PMID: 31836698; PMCID: PMC6910906.
  50. Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, Melton LJ 3rd. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002 Feb 21;346(8):564-9. doi: 10.1056/NEJMoa01133202. PMID: 11856795.
  51. Kyle RA, Remstein ED, Therneau TM, Dispenzieri A, Kurtin PJ, Hodnefield JM, Larson DR, Plevak MF, Jelinek DF, Fonseca R, Melton LJ 3rd, Rajkumar SV. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med. 2007 Jun 21;356(25):2582-90. doi: 10.1056/NEJMoa070389. PMID: 17582068.
  52. Rajkumar SV, Kumar S, Lonial S, Mateos MV. Smoldering multiple myeloma current treatment algorithms. Blood Cancer J. 2022 Sep 5;12(9):129. doi: 10.1038/s41408-022-00719-0. PMID: 36064707; PMCID: PMC9445066.
  53. Mateos MV, Martínez-López J, Rodriguez Otero P, González-Calle V, Gonzalez MS, Oriol A, Gutiérrez NC, Ríos-Tamayo R, Rosiñol L, Alvarez Rivas MA, Bargay J, Gonzalez-Rodriguez AP, Alegre A, Escalante F, Iñigo Rodríguez MB, De La Rubia J, Teruel AI, de Arriba F, Palomera L, Hernández MT, Lopez Jiménez J, Reinoso-Segura M, García Mateo A, Ocio EM, Paiva B, Puig N, Cedena MT, Bladé J, Lahuerta JJ, San-Miguel JF; Spanish Myeloma Group (GEM-Pethema). Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance. J Clin Oncol. 2024 Sep 20;42(27):3247-3256. doi: 10.1200/JCO.23.02771. Epub 2024 Jul 22. PMID: 39038268; PMCID: PMC11404760.
  54. Dispenzieri A, Stewart AK, Chanan-Khan A, Rajkumar SV, Kyle RA, Fonseca R, Kapoor P, Bergsagel PL, McCurdy A, Gertz MA, Lacy MQ, Lust JA, Russell SJ, Zeldenrust SR, Reeder C, Roy V, Buadi F, Dingli D, Hayman SR, Leung N, Lin Y, Mikhael J, Kumar SK. Smoldering multiple myeloma requiring treatment: time for a new definition? Blood. 2013 Dec 19;122(26):4172-81. doi: 10.1182/blood-2013-08-520890. Epub 2013 Oct 21. PMID: 24144641; PMCID: PMC3952477.
  55. Mateos MV, Hernández MT, Giraldo P, de la Rubia J, de Arriba F, López Corral L, Rosiñol L, Paiva B, Palomera L, Bargay J, Oriol A, Prosper F, López J, Olavarría E, Quintana N, García JL, Bladé J, Lahuerta JJ, San Miguel JF. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med. 2013 Aug 1;369(5):438-47. doi: 10.1056/NEJMoa1300439. PMID: 23902483.
  56. Witzig TE, Laumann KM, Lacy MQ, Hayman SR, Dispenzieri A, Kumar S, Reeder CB, Roy V, Lust JA, Gertz MA, Greipp PR, Hassoun H, Mandrekar SJ, Rajkumar SV. A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma. Leukemia. 2013 Jan;27(1):220-5. doi: 10.1038/leu.2012.236. Epub 2012 Aug 20. PMID: 22902362; PMCID: PMC3912579.
  57. Landgren O, Waxman AJ. Multiple myeloma precursor disease. JAMA. 2010 Dec 1;304(21):2397-404. doi: 10.1001/jama.2010.1713. PMID: 21119086; PMCID: PMC6860969.
  58. Rajkumar SV, Lacy MQ, Kyle RA. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Blood Rev. 2007 Sep;21(5):255-65. doi: 10.1016/j.blre.2007.01.002. Epub 2007 Mar 26. PMID: 17367905.
  59. Mateos MV, San Miguel JF. New approaches to smoldering myeloma. Curr Hematol Malig Rep. 2013 Dec;8(4):270-6. doi: 10.1007/s11899-013-0174-1. PMID: 23975678.
  60. Gozzetti A, Defina M, Bocchia M. Treatment of smoldering multiple myeloma. Nature Reviews Clinical Oncology. 2013;10(12):724.


Comments


Publish with JBRES — Peer-reviewed, multidisciplinary Open Access with rapid review, DOI, and global visibility.
Double-Blind CrossRef DOI Discoverable